-
Je něco špatně v tomto záznamu ?
Effect of two-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study
J. Veselka, D. Zemánek, P. Hájek, M. Malý, R. Adlová, L. Martinkovičová, D. Tesař
Jazyk angličtina Země Spojené státy americké
Typ dokumentu randomizované kontrolované studie, práce podpořená grantem
- MeSH
- angina pectoris terapie MeSH
- dospělí MeSH
- infarkt myokardu prevence a kontrola MeSH
- kyseliny heptylové aplikace a dávkování MeSH
- lidé středního věku MeSH
- lidé MeSH
- multivariační analýza MeSH
- prospektivní studie MeSH
- pyrroly aplikace a dávkování MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- statiny aplikace a dávkování MeSH
- troponin I krev MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
Both randomized and observational studies have suggested that pretreatment with statins may reduce the incidence of periprocedural myocardial infarction (PMI) in patients with stable angina during elective percutaneous coronary intervention (PCI). The purpose of this randomized study (Clinical Trial Registration No. NCT00469326) was to investigate the effect of 2-day atorvastatin therapy on the incidence of PMI in patients with stable angina pectoris undergoing elective PCI. A total of 200 patients with stable angina pectoris who were not taking statins and who had been referred for PCI were enrolled and randomized (ratio 1:1) to a 2-day pretreatment regimen with atorvastatin 80 mg/day and subsequent PCI or immediate PCI. The serum concentration of creatine kinase-MB mass and troponin I were measured before and 16 to 24 hours after PCI. The incidence of PMI was assessed using established criteria. Of the patients, 10% in the atorvastatin group and 12% in the control group had a postprocedural creatine kinase-MB mass elevation > or =3 times the upper limit of normal (p = 0.65). The incidence of PMI as determined by the postinterventional release of troponin I > or =3 times the upper limit of normal was 17% in the atorvastatin group and 16% in the control group (p = 0.85). The median creatine kinase-MB mass peak after PCI was 1.46 ng/ml (interquartile range 0.83 to 2.52) in the atorvastatin group and 1.40 ng/ml (interquartile range 0.90 to 2.54) in the control group (p = 0.70). The median peak troponin I level after PCI was 0.100 ng/ml (0.096 to 0.385) in the atorvastatin group and 0.100 ng/ml (0.60 to 0.262) in the control group (p = 0.54). On multivariate analysis, the only independent predictor of PMI was patient age (odds ratio 1.09, 95% confidence interval 1.025 to 1.159, p = 0.006). In conclusion, in the present study 2-day pre-PCI therapy with atorvastatin did not reduce the occurrence of PMI in patients with stable angina pectoris undergoing elective PCI.
Citace poskytuje Crossref.org
- 000
- 03858naa 2200457 a 4500
- 001
- bmc11016610
- 003
- CZ-PrNML
- 005
- 20121221095152.0
- 008
- 110628s2009 xxu e eng||
- 009
- AR
- 024 __
- $a 10.1016/j.amjcard.2009.04.048 $2 doi
- 035 __
- $a (PubMed)19699335
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Veselka, Josef, $d 1965- $7 pna2005261820
- 245 10
- $a Effect of two-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study / $c J. Veselka, D. Zemánek, P. Hájek, M. Malý, R. Adlová, L. Martinkovičová, D. Tesař
- 314 __
- $a Department of Cardiology, CardioVascular Center, University Hospital, Charles University Motol Medical School I, Prague, Czech Republic. veselka.josef@seznam.cz
- 520 9_
- $a Both randomized and observational studies have suggested that pretreatment with statins may reduce the incidence of periprocedural myocardial infarction (PMI) in patients with stable angina during elective percutaneous coronary intervention (PCI). The purpose of this randomized study (Clinical Trial Registration No. NCT00469326) was to investigate the effect of 2-day atorvastatin therapy on the incidence of PMI in patients with stable angina pectoris undergoing elective PCI. A total of 200 patients with stable angina pectoris who were not taking statins and who had been referred for PCI were enrolled and randomized (ratio 1:1) to a 2-day pretreatment regimen with atorvastatin 80 mg/day and subsequent PCI or immediate PCI. The serum concentration of creatine kinase-MB mass and troponin I were measured before and 16 to 24 hours after PCI. The incidence of PMI was assessed using established criteria. Of the patients, 10% in the atorvastatin group and 12% in the control group had a postprocedural creatine kinase-MB mass elevation > or =3 times the upper limit of normal (p = 0.65). The incidence of PMI as determined by the postinterventional release of troponin I > or =3 times the upper limit of normal was 17% in the atorvastatin group and 16% in the control group (p = 0.85). The median creatine kinase-MB mass peak after PCI was 1.46 ng/ml (interquartile range 0.83 to 2.52) in the atorvastatin group and 1.40 ng/ml (interquartile range 0.90 to 2.54) in the control group (p = 0.70). The median peak troponin I level after PCI was 0.100 ng/ml (0.096 to 0.385) in the atorvastatin group and 0.100 ng/ml (0.60 to 0.262) in the control group (p = 0.54). On multivariate analysis, the only independent predictor of PMI was patient age (odds ratio 1.09, 95% confidence interval 1.025 to 1.159, p = 0.006). In conclusion, in the present study 2-day pre-PCI therapy with atorvastatin did not reduce the occurrence of PMI in patients with stable angina pectoris undergoing elective PCI.
- 590 __
- $a bohemika - dle Pubmed
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a angina pectoris $x terapie $7 D000787
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a kyseliny heptylové $x aplikace a dávkování $7 D006538
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a statiny $x aplikace a dávkování $7 D019161
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a multivariační analýza $7 D015999
- 650 _2
- $a infarkt myokardu $x prevence a kontrola $7 D009203
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a pyrroly $x aplikace a dávkování $7 D011758
- 650 _2
- $a troponin I $x krev $7 D019210
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Zemánek, David, $d 1972- $7 xx0079099
- 700 1_
- $a Hájek, Petr $7 xx0071248
- 700 1_
- $a Malý, Martin, $d 1966- $7 mzk2004241073
- 700 1_
- $a Adlová, Radka $7 xx0139523
- 700 1_
- $a Martinkovičová, Lucia. $7 _AN033108
- 700 1_
- $a Tesař, David $7 xx0081874
- 773 0_
- $t American Journal of Cardiology $w MED00000236 $g Roč. 104, č. 5 (2009), s. 630-633
- 910 __
- $a ABA008 $b x $y 2
- 990 __
- $a 20110720115208 $b ABA008
- 991 __
- $a 20121221095236 $b ABA008
- 999 __
- $a ok $b bmc $g 864023 $s 726391
- BAS __
- $a 3
- BMC __
- $a 2009 $x MED00000236 $b 104 $c 5 $d 630-633 $m The American journal of cardiology $n Am J Cardiol
- LZP __
- $a 2011-3B09/BBjvme